DRUG SUPPLIED DOSE COMMENTS
ANAKINRA (Paeds)
(Kineret)

Mechanism of action:

Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI)



Ref: 44, 325, 326


Last update: 2021-06-22		 Injection: 100 mg PFS
Rheumatic diseases: eg. systemic onset juvenile idiopathic arthritis, periodic fever syndromes.

1-2 mg/kg/dose SC once daily (Max 100 mg/dose).

If no response, may double dose at 2 week intervals to a max of 4 mg/kg/dose (Max 200 mg/dose).

 Adverse effects include injection site irritation, headache, diarrhea, nausea, vomiting, fever and infection.

Risk of infection: do not use in patients with severe infection. All patients should be evaluated for both acute and latent tuberculosis before starting treatment.

Administration of live vaccinations to patients on anakinra not recommended.

Standard Prescription:

__ mg/kg/dose SC once daily